Launch of Gynazole•1® in Switzerland in March 2007
March, 30th, 2007

OM PHARMA Meyrin/Geneva launches Gynazole•1® this month in Switzerland. This innovative cream for the treatment of vulvo-vaginal yeast infections contains butoconazole nitrate (2%) as active principle. Thanks to its high bioadhesiveness to the vaginal cell wall, Gynazole•1® brings rapid relief of symptoms of vulvovaginal mycoses in less than 4 hours. A unique pre-filled device allows the application of a single dose at any time of the day or night. Gynazole•1® is the result of the patented drug delivery technology VagiSite® developed in the USA by KV Pharmaceutical Company. www.gynazole-1.com

Top of the page